Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Best Cost Effective Care of Cutaneous T Cell Lymphoma
Description
The presentation focuses on the cost-effective care of cutaneous T-cell lymphoma (CTCL), which includes various skin-affecting non-Hodgkin lymphomas. Approximately 2,500 to 3,000 new cases occur annually in the U.S. with treatment efficacy varying based on disease stage. Early-stage CTCL is typically treated with skin-directed therapies, while advanced stages require systemic treatments as well. Key findings reveal that CTCL is the most expensive skin disease per person, with costs far exceeding those of atopic dermatitis. Treatment costs for topical medications, phototherapy, and various systemic therapies were examined, revealing significant disparities—local radiation emerged as the most cost-effective treatment for early-stage patients, followed by phototherapy. In a more aggressive context, agents like gemcitabine and liposomal doxorubicin were identified as viable options for reducing tumor burden. The talk emphasizes a balance between effective treatment strategies and associated costs, suggesting combining therapies for optimal outcomes, particularly for aggressive or refractory cases. Additionally, considerations for long-term disease control and maintaining patient quality of life are paramount. The session concluded with a focus on the need for further cost-effectiveness studies and integrating treatment goals to improve patient care in CTCL.
View moreConclusions
- Localized radiation therapy is the most cost effective option for early-stage cutaneous T-cell lymphoma (CTCL).
- Narrowband UVB phototherapy follows closely in cost effectiveness for early-stage CTCL.
- Topical corticosteroids are recommended as initial treatment for localized early-stage disease.
- In cases of more extensive skin disease, consider narrowband UVB as a first-line treatment.
- Bexarotene gel is largely considered ineffective and cost prohibitive for clinical use in CTCL.
- Systemic treatments such as methotrexate and interferon alpha are cost effective options for advanced CTCL stages.
- Extracorporeal photopheresis represents a well-tolerated treatment option, balancing cost with therapeutic benefit.
- Stem cell transplants offer potential for cure but come with significant cost and recovery concerns.
- Cost analyses should account for quality of life impacts and synergistic effects of combination therapies.
- Agar NS et al. JCO. 2010;28: 4730-4739.
- Mourad A, et al. JID. 2020; 2:495-497.
- Lim et al. JAAD 2018;78(1):129-140.
- Xia FD et al, JAAD 2019 Feb;80(2):485-492.
- Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003; 139:165.
- Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134:949.
- Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther 2003; 16:283.
- Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013; 149:25.
- Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138:325.
- Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003; 49:801.
- Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:275.
- Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1057.
- Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92:32.
- Thomas TO, Agrawal P, Guitart J, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 2013; 85:747.
- Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128:931.
- Gathers RC, Scherschun L, Malick F, et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002; 47:191.
- Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 1987; 123:897.
- Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-Il clinical trials. J Am Acad Dermatol 2015; 72:286.
- Kim YH, Tavallaee M, Sundram U, et al. Phase Il Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 2015; 33:3750.
- Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017.
- Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol 2016; 7:171.
- Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19:1192.